Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 7.61

From 52W high−30.35%

Volume5.27M

Market capCNY 6.59B

P/E (TTM)50.5x

P/S (TTM)7.9x

Div yield0.84%

Key dataSep 18, 2026

Open

CNY 7.61

From 52W high

−30.35%

Volume

5.27M

Market cap

CNY 6.59B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

26.3x

P/E (TTM)

50.5x

RSI (14)

41.5

MomentumView details →

1D Return

−1.98%

YTD Return

−23.59%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

50.5x

EV/EBITDA

26.3x

EV/Sales

7.1x

P/S (TTM)

7.9x

P/B (TTM)

2.9x

ProfitabilityView details →

Gross Margin

54.06%

Net Margin

13.59%

EBITDA Margin

26.95%

ROE (TTM)

4.56%

ROA (TTM)

3.42%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

−0.78%

EPS YoY

−48.75%

FCF YoY

−9.19%

Revenue CAGR 3Y

+1.22%

EPS CAGR 3Y

−26.92%

EBITDA YoY

—

MomentumView details →

1D Return

−1.98%

YTD Return

−23.59%

1Y Return

−29.55%

RSI (14)

41.5

vs 50D SMA

−3.93%

vs 200D SMA

−17.17%

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

2.64x

Quick Ratio

2.12x

Div Yield

0.84%

Div Rate

CNY 0.06

Div Growth 1Y

−36.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

794.80M

Net Income (TTM)

108.03M

Op. CF (TTM)

120.43M

Latest newsMore news →

Aoxiang Pharmaceutical announced its first-half 2026 results with revenue of 468 million yuan, down 2.96% year-on-year, and net profit attributable to shareholders of 120 million yuan, down 29.23% year-on-year.23d ago

Aoxiang Pharmaceutical's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical received drug registration certificates from China's National Medical Products Administration for ruxolitinib phosphate tablets in 5mg, 15mg, and 20mg strengths, deemed equivalent to passing generic consistency evaluation.30d ago

Similar companies

CG Oncology, Inc. Common stockCGON 艾迪药业688488.SH Rhythm Pharmaceuticals, Inc.RYTM Arcellx, Inc.ACLX XD昊海生688366.SH Tennor Therap-b06872.HK Find similar companies →

Latest newsMore news →

Aoxiang Pharmaceutical announced its first-half 2026 results with revenue of 468 million yuan, down 2.96% year-on-year, and net profit attributable to shareholders of 120 million yuan, down 29.23% year-on-year.23d ago Aoxiang Pharmaceutical's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical received drug registration certificates from China's National Medical Products Administration for ruxolitinib phosphate tablets in 5mg, 15mg, and 20mg strengths, deemed equivalent to passing generic consistency evaluation.30d ago